HTDS Hard To Treat Diseases Inc (CE)

SHENZHEN, China, March 2 /PRNewswire-FirstCall/ -- Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its China based subsidiary Mellow Hope update shareholders on the company's 2009 revenues and profits. With Fiscal Year ending on December 31st, HTDS announces that the company generated $5.39 million USD in Gross Revenues, with profits reaching $621,000 USD in 2009. The company gladly shares these sound numbers with the shareholders, and expects to increase its revenues in 2010. As the company does not subscribe to Pink Sheets filing service, the detailed financials are posted on HTDS IR company web site section "CLIENT SUPPORT" TAB, http://www.minamargroup.net/, or this direct link http://minamarmarketinggroup.helpserve.com/, and HTDS web site. A source close to HTDS, said, "We had a great 2009, and we don't expect any less from 2010. In 2009 we pushed our company deeper into the international vaccine trade, completed a number of solid deals and hoisted HTDS' name on the international markets. As 2010 progresses, we continue working on a number of promising market opportunities like those in India and Chile. HTDS internal projects are also well underway: We just completed the merger with Collagenna Skin Care which will market under the Melem Secrets brand. This will jumpstart our expansion into cosmetics market; and continue our assessment of the regenerative medicine and the stem cell bank projects in Europe. We have a lot on our plate today, but these substantial changes will create stronger and well-diversified HTDS for the future. Moving forward, revenues from Collagenna will also be included in our balance sheets." The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB, http://www.minamargroup.net/, or this direct link http://minamarmarketinggroup.helpserve.com/ should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support site to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link http://www.minamargroup.net/helpdesk. Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas, where amongst other things they continuously spread false rumours, dark propaganda and innuendos in order to manipulate the trading patterns and thwart company plans for their own "quick profits" and self serving needs. The company and its supporters are monitoring these activities and those are promptly being reported on the http://www.stockbasher.com/ web site. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities and others are taking against these individuals. To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news releases, please subscribe or opt in mailer at http://www.minamargroup.com/updates. Safe Harbor Statement Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact http://www.minamargroup.com/helpdesk DATASOURCE: Hard to Treat Diseases CONTACT: For medical and scientific dialogue inquiry only, pleasecontact medicalinfo@htdsmedical.com; For any corporate matters, please contacthttp://www.minamargroup.com/helpdesk

Copyright